By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is overwhelmingly bearish on the proposed $500k retirement plan relying on ARCC, ET, and PFE. They highlight lack of diversification, dependence on perpetually high dividends, sensitivity to macro cycles, and sequence-of-returns risk as major concerns.
Risk: Sequence-of-returns risk and potential dividend cuts before price crashes, leading to catastrophic principal loss and income shortfall.
Opportunity: None identified.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Is it possible to retire on $500,000? Yes, but it won't be easy.
The median U.S. household income is $88,510, according to Motio Research. To make that much money with an initial investment of $500,000, you'd need an annual return of 17.7%. It's possible to reach that level, but quite difficult to pull off.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
We haven't included Social Security yet, though. The average Social Security benefit for a retired worker is around $2,179 per month, or $26,148 per year. With this benefit included, you'd need to achieve an annual return of roughly 12.5% on a $500,000 portfolio to make the median household income. However, if you're married and both spouses receive the average Social Security retirement benefit, the needed annual return falls to 7.2%.
The good news is that some stocks pay dividends that could help you get close to (or even above) that magic level. If you want to retire on $500,000, here are three stocks to buy and never sell.
Ares Capital (NASDAQ: ARCC) is the largest publicly traded business development company (BDC). It has a $21.5 billion highly diversified portfolio. The portfolio's top 10 investments account for 10.4% of total assets, compared with 23.7% for Ares Capital's BDC peers.
This BDC leader offers an especially juicy dividend yield of 10.6%. Such an ultra-high yield usually raises red flags, but not in Ares Capital's case. The company has paid stable or increasing dividends for 67 consecutive quarters, a period that included the financial crisis of 2007-2009 and the COVID-19 pandemic.
Ares Capital continues to generate ample earnings to cover its distribution. It also has spillover income (undistributed taxable income carried forward) that could be used to fund future distributions if earnings are pressured.
What about Ares Capital's exposure to software-as-a-service (SaaS) companies that could be disrupted by artificial intelligence (AI)? Software and services companies make up over one-fifth of the BDC's portfolio. However, around 85% of these companies are considered low risk and "more poised to benefit from AI than to be disrupted," according to CEO Kort Schnabel.
Energy Transfer LP (NYSE: ET) is one of the top midstream energy companies in North America. It operates over 140,000 miles of pipelines that transport natural gas, natural gas liquids (NGLs), crude oil, and refined products.
The limited partnership pays an attractive distribution yield of roughly 7.2%. Energy Transfer's distribution coverage ratio is healthy. Management expects to increase the distribution by 3% to 5% per year on average.
The ongoing rapid build-out of AI data centers serves as a significant tailwind for Energy Transfer. As a case in point, the midstream company signed agreements with Oracle (NYSE: ORCL) last year to supply natural gas to three data centers.
This pipeline stock is also highly resilient when oil and gas prices fluctuate. Around 90% of Energy Transfer's adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) are fee-based and insulated from commodity prices.
Pfizer (NYSE: PFE) is the best-known of these three income stocks. The big pharmaceutical company markets blockbuster drugs, including the blood thinner Eliquis, cancer therapies Ibrance, Padcev, and Xtandi, and the rare heart disease drug Vyndaqel.
The drugmaker's forward dividend yield currently tops 6.8%. Pfizer has increased its dividend for 16 consecutive years and has paid a dividend for 350 consecutive quarters. Management remains committed to maintaining and growing the dividend over the long run.
To be sure, Pfizer faces some challenges. Its COVID-19 product sales are a shadow of what they once were. Several key products will lose patent exclusivity over the next few years, notably including Eliquis, Ibrance, and Xtandi.
However, the company has invested in developing new products and closing acquisitions to bolster its pipeline. As a result, Pfizer expects to deliver solid revenue growth beyond 2028, once the worst of its patent cliff is over.
Ares Capital, Energy Transfer, and Pfizer should be able to help make retiring on $500,000 a real possibility. There is an important caveat, though: Investing in only three stocks isn't wise. It's important to create a well-diversified portfolio.
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $417,305! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,293,148!
Now, it’s worth noting Stock Advisor’s total average return is 936% — a market-crushing outperformance compared to 209% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of June 21, 2026. *
Keith Speights has positions in Ares Capital, Energy Transfer, and Pfizer. The Motley Fool has positions in and recommends Ares Capital, Oracle, and Pfizer. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"A 500k retirement plan built on ARCC, ET, and PFE is unlikely to be sustainable due to dividend-coverage risk, rate sensitivity, and diversification gaps."
The article promotes a $500k retirement plan built on three high-yield names: ARCC (BDC) ~10.6% yield, ET ~7.2% yield, and PFE ~6.8% forward yield. While appealing, the thesis glosses over real risks: lack of diversification, dependence on perpetually high or growing dividends, and sensitivity to macro cycles. BDCs like ARCC face credit risk and rate leverage that can compress distributions in a downturn; ET’s payout could be pressured by capital markets and project cash-flow shifts even if much EBITDA is fee-based; Pfizer’s dividend growth faces patent cliffs and pipeline execution risk. Tax drag and withdrawal-rate reality further complicate a 3-stock plan. Missing is a stress-test, fee/tax impact, and total-return view.
The strongest counterpoint is that a 3-stock, high-yield plan is extremely fragile: a recession or higher rates could trigger dividend cuts or cuts in growth, and diversification gaps would magnify drawdowns vs. a balanced portfolio.
"High-dividend yield strategies often mask underlying capital erosion and should not be the foundation of a $500,000 retirement plan."
This article promotes a 'yield-chasing' strategy that ignores the fundamental risk of total return degradation. While ARCC, ET, and PFE offer high current income, they are structurally flawed for a retiree's core portfolio. ARCC is a BDC sensitive to interest rate volatility and credit spreads; if the economy slows, its net asset value (NAV) will likely contract. Pfizer is a 'value trap' currently facing a patent cliff that threatens its long-term dividend coverage. Relying on these for a $500,000 retirement nest egg assumes these companies can maintain payouts despite cyclical headwinds. Investors are better served by lower-yielding, high-growth assets that provide capital appreciation, rather than betting on high-payout vehicles that often erode principal over time.
If interest rates remain 'higher for longer,' ARCC’s floating-rate loan portfolio could continue to generate superior net investment income, potentially outperforming broader market indices.
"Dividend yield alone is not total return; this three-stock portfolio likely generates 8-9% blended yield but faces capital erosion, tax drag, and sector-specific headwinds (BDC credit risk, energy transition, pharma patent cliffs) that make it inadequate for a 30-year retirement horizon."
The article's math is fundamentally broken. Retiring on $500k requires either 12.5% annual returns (solo) or 7.2% (married couple with Social Security). ARCC at 10.6% yield looks seductive, but BDC dividends are often return-of-capital disguised as income—taxed as ordinary income while eroding principal. ET's 7.2% yield depends on commodity-insulated fee-based EBITDA, but midstream faces energy transition risk the article ignores. PFE's 6.8% yield plus growth doesn't bridge the gap. The real problem: this portfolio likely underperforms 8-10% needed to sustain $500k withdrawals after taxes and inflation over 30+ years. The article conflates yield with total return.
If you're married and already receiving $52k/year in Social Security, a 7.2% yield on $500k ($36k) gets you to $88k household income—exactly the article's target. Diversified dividend stocks with modest 3-5% annual growth could work if you're disciplined about not touching principal.
"Concentrating $500k in three high-yield names with embedded credit, regulatory, and patent risks makes the retirement-income thesis far more fragile than the article presents."
The article's core pitch—that ARCC's 10.6% yield, ET's 7.2% distribution, and PFE's 6.8% payout can bridge a $500k portfolio to median household income alongside Social Security—overstates sustainability. ARCC's BDC book carries concentrated credit exposure despite diversification claims, ET's fee-based EBITDA still faces pipeline permitting and rate risks, and PFE's post-2028 growth hinges on unproven pipeline replenishment after Eliquis and Ibrance cliffs. The 'never sell' framing ignores sequence-of-returns danger and the explicit diversification warning buried at the end.
Dividend coverage ratios remain healthy today and management guidance for 3-5% annual growth at ET plus ARCC's spillover income could extend payouts longer than credit or patent risks imply, making the income stream more durable than historical high-yield defaults suggest.
"NAV compression and credit-spread risk can erode distributions and total return, even if net investment income looks solid."
Gemini’s claim that ARCC’s floating-rate BDC book will outperform in 'higher for longer' environments ignores a critical risk: NAV compression as credit spreads widen and mid-market loan marks fall, which can crush distributions long before NII reflects in fund cash flow. Even if NII stays solid, price volatility and principal erosion hit total return, making a 3-stock retiree anchor fragile, especially vs diversified income or growth-inclined ballast.
"A three-stock high-yield portfolio lacks the defensive ballast required to survive early-retirement market volatility without forcing principal liquidation."
Claude, your reliance on Social Security to bridge the math gap ignores the 'sequence of returns' risk inherent in this 3-stock portfolio. If a market correction hits early in retirement, those high-yield names will likely see deeper drawdowns than a broad index, forcing a retiree to sell shares at depressed prices just to maintain the $88k income floor. Relying on dividends to cover the shortfall assumes no dividend cuts occur during that exact period of market stress.
"BDC dividend cuts precede NAV recovery, so a distribution-dependent retiree gets hit twice—income loss plus delayed price recovery."
Gemini nails sequence-of-returns risk, but misses that it cuts both ways. A retiree *forced to sell* ARCC at NAV compression during credit stress faces catastrophic principal loss—but one *living on distributions alone* avoids that trap entirely. The real vulnerability: ARCC's dividend gets cut *before* the price crashes, leaving the retiree with neither income nor capital. That's worse than Gemini's drawdown scenario.
"ET permitting risks could align with ARCC credit stress to hit two holdings at once."
Claude flags ARCC dividend cuts preceding NAV drops, yet this ignores how ET's fee-based EBITDA still hinges on timely pipeline completions amid 2025 permitting backlogs at FERC. A simultaneous slowdown in energy infrastructure approvals would pressure ET distributions just as ARCC faces credit deterioration, creating correlated income shocks across two of the three holdings that Social Security cannot fully buffer for the $500k plan.
The panel consensus is overwhelmingly bearish on the proposed $500k retirement plan relying on ARCC, ET, and PFE. They highlight lack of diversification, dependence on perpetually high dividends, sensitivity to macro cycles, and sequence-of-returns risk as major concerns.
None identified.
Sequence-of-returns risk and potential dividend cuts before price crashes, leading to catastrophic principal loss and income shortfall.